M. Sinn

885 total citations · 1 hit paper
19 papers, 517 citations indexed

About

M. Sinn is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Sinn has authored 19 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Surgery and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Sinn's work include Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). M. Sinn is often cited by papers focused on Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). M. Sinn collaborates with scholars based in Germany, United Kingdom and Austria. M. Sinn's co-authors include Uwe Pelzer, Hanno Riess, Marcus Bahra, Philipp Lohneis, Jana K. Striefler, Helmut Oettle, Bernd Dörken, Jens Stieler, Carsten Denkert and Karin Jordan and has published in prestigious journals such as Journal of Hepatology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

M. Sinn

17 papers receiving 509 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

2023 172 citations Anna Falanga, Cihan Ay et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Sinn Germany	9	291	142	106	103	102	19	517
Lorenzo Gervaso Italy	10	208 0.7×	202 1.4×	57 0.5×	144 1.4×	110 1.1×	46	447
A. Vignoli Italy	5	136 0.5×	158 1.1×	76 0.7×	84 0.8×	99 1.0×	7	499
Charlene Mantia United States	13	281 1.0×	139 1.0×	134 1.3×	98 1.0×	244 2.4×	52	657
J.L. Balibrea Spain	12	150 0.5×	201 1.4×	138 1.3×	143 1.4×	106 1.0×	18	562
Ella Grilz Austria	15	166 0.6×	381 2.7×	69 0.7×	259 2.5×	98 1.0×	23	862
Matteo Brighenti Italy	12	628 2.2×	66 0.5×	97 0.9×	51 0.5×	316 3.1×	38	869
AK Kakkar United Kingdom	7	161 0.6×	416 2.9×	164 1.5×	264 2.6×	88 0.9×	11	755
Kuhn‐Uk Lee South Korea	8	417 1.4×	67 0.5×	256 2.4×	42 0.4×	410 4.0×	9	714
Feras Abu Saadeh Ireland	11	73 0.3×	178 1.3×	65 0.6×	100 1.0×	46 0.5×	41	483
D. Anthony Barcel United States	4	78 0.3×	211 1.5×	115 1.1×	68 0.7×	41 0.4×	8	472

Countries citing papers authored by M. Sinn

Since Specialization

Citations

This map shows the geographic impact of M. Sinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Sinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Sinn more than expected).

Fields of papers citing papers by M. Sinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Sinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Sinn. The network helps show where M. Sinn may publish in the future.

Co-authorship network of co-authors of M. Sinn

This figure shows the co-authorship network connecting the top 25 collaborators of M. Sinn. A scholar is included among the top collaborators of M. Sinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Sinn. M. Sinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kasper‐Virchow, Stefan, Ralf‐Dieter Hofheinz, Sebastian Stintzing, et al.. (2024). LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316). Annals of Oncology. 35. S1218–S1218. 1 indexed citations

Falanga, Anna, Cihan Ay, Marcello Di Nisio, et al.. (2023). Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Annals of Oncology. 34(5). 452–467. 172 indexed citations breakdown →

Stein, Alexander, Lisa Paschold, Joseph Tintelnot, et al.. (2021). LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217). Annals of Oncology. 32. S1331–S1331. 9 indexed citations

Sinn, M., et al.. (2021). 71/m in reduziertem Allgemeinzustand mit Sklerenikterus. Der Onkologe. 27(S1). 109–113.

Kasper, Stefan, Ralf‐Dieter Hofheinz, Sebastian Stintzing, et al.. (2020). 438P Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO. Annals of Oncology. 31. S427–S428. 1 indexed citations

Sinn, M., Torsten Liersch, Hanno Riess, et al.. (2020). CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results. European Journal of Cancer. 138. 172–181. 22 indexed citations

Heinrich, Kathrin, Lisa Miller‐Phillips, Amanda Tufman, et al.. (2020). AIO-MentorUs – gelebte Nachwuchsförderung in der AIO. Forum. 35(1). 9–12. 2 indexed citations

Pape, Ulrich F., Stefan Kasper, M. Sinn, et al.. (2019). Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study. Annals of Oncology. 30. v278–v278. 1 indexed citations

Pelzer, Uwe & M. Sinn. (2019). Ist nicht obligat: histologische Sicherung vor neoadjuvanter Therapie des Pankreaskarzinoms. Der Onkologe. 25(8). 658–660.

10.

Sinn, M., Jan Budczies, Frédérik Damm, et al.. (2017). TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study. Annals of Oncology. 28. v251–v251. 3 indexed citations

11.

Knitter, Sebastian, Marcus Bahra, Moritz Schmelzle, et al.. (2017). Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. European Journal of Surgical Oncology. 43(9). 1668–1681. 39 indexed citations

12.

Sinn, M., Hanno Riess, Jens Stieler, et al.. (2015). Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trial. European Journal of Cancer. 51(12). 1546–1554. 34 indexed citations

13.

Wege, Henning, Wolf O. Bechstein, John Bridgewater, et al.. (2015). P1310 : Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) – a randomized, multidisciplinary, multinational phase III trial. Journal of Hepatology. 62. S845–S845. 1 indexed citations

14.

Sinn, M., Carsten Denkert, Jana K. Striefler, et al.. (2014). α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. British Journal of Cancer. 111(10). 1917–1923. 112 indexed citations

15.

Sinn, M., Jana K. Striefler, Judith Lindner, et al.. (2014). SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Annals of Oncology. 25(5). 1025–1032. 63 indexed citations

16.

Sinn, M., Torsten Liersch, Klaus Gellert, et al.. (2014). Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer. Annals of Oncology. 25. v1–v1. 16 indexed citations

17.

Pelzer, Uwe, M. Sinn, Bernd Dörken, et al.. (2013). Blood group determinates incidence for pancreatic cancer in Germany. Frontiers in Physiology. 4. 118–118. 32 indexed citations

18.

Sinn, M.. (1989). Analgetika und Schmerztherapie. Von M. Albinus und V. Hempel. Wiss. Verlagsges. mbH. Stuttgart 1988. 211 S., 25 Abb., 27 Tab., kart. DM 36,—. Vorzugspreis für Bezieher der Reihe DM 28,80. Pharmazie in unserer Zeit. 18(2). 63–64. 3 indexed citations

19.

Holdorff, B., M. Sinn, & Georg A. Roth. (1977). [Propranolol for prophylaxis of migraine (author's transl)].. PubMed. 72(25). 1115–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact